PEspeaks

Aug 01, 2012
Pharmaceutical Executive
The decisions you make today about patents – what, when and where to file – could have implications tantamount to billions of dollars in R&D investment and sales over the next two decades.
Aug 01, 2012
Pharmaceutical Executive
FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS
Aug 01, 2012
Pharmaceutical Executive
The prospect that antiretroviral drugs could prevent HIV infection in high-risk populations was the big news emerging from last month’s International AIDS Conference in Washington, DC.
Jul 30, 2012
Pharmaceutical Executive
Patient groups are a growing force, not just in the debate around tactical areas of medical specialities, but also on the vital question of pricing and reimbursement rules. But will their voices be heard? Reflector reports.
Jul 27, 2012
Pharmaceutical Executive
The time and cost of developing new drugs are rising, venture capitalists make no return on investments in biopharma R&D, and other countries are boosting support in this area while U.S. policy makers propose funding cuts for the National Institutes of Health (NIH).
Jul 25, 2012
Pharmaceutical Executive
Industry is finding it harder to secure market access and payer uptake for new products. Innovative contracting may offer a solution. But is it working? Andrea Sobrio reports.
Jul 24, 2012
Pharmaceutical Executive
It’s an unusual sight in the UK — a television commercial for a Big Pharma company. But among the cultural and commercial innovations being attributed to the London Olympic Games is GSK’s first UK consumer-facing corporate brand campaign, showcasing its anti-doping operations.
Jul 20, 2012
Pharmaceutical Executive
At CBI’s 7th Annual Rare Disease and Orphan Drug Leadership Congress, speakers and attendees identified areas where pharma can improve the way it approaches rare disease and treatment.
Jul 18, 2012
Pharmaceutical Executive
The European Commission has followed the UK government’s plans to make all publicly funded scientific research available for free, announcing that it will improve access to scientific information in Europe.
Jul 18, 2012
Pharmaceutical Executive
Like governors in the US vowing to block Medicaid expansion in their home states, local primary care trusts (PCTs) in the UK don’t always follow national guidelines on drug access due to budgetary concerns.
native1_300x100
lorem ipsum